Nanocarriers: more than tour de force for thymoquinone

References

• Boadu AA, Asase A. Documentation of herbal medicines used for the treatment and management of human diseases by some communities in southern Ghana. Evid Based Complement Alternat Med. 2017;11-12:1–12.
   PubMed Web of Science ®Google Scholar
• Negi P, Rathore C, Sharma G, et al. Thymoquinone a potential therapeutic molecule from the plant nigellasativa: role of colloidal carriers in its effective delivery. Recent Pat Drug Deliv Formul. 2018;112(1):3–22.
   Google Scholar
• Yimer EM, Tuem KB, Karim A, et al. Nigella sativa L. (Black Cumin): a promising natural remedy for wide range of illnesses. Evid Based Complement Alternat Med. 2019;6:1–16.
   PubMed Web of Science ®Google Scholar
• Darakhshan S, Pour AB, Colagar AH. Thymoquinone and its therapeutic potentials. Pharmacol Res. 2015;95-96:138–158.
   Web of Science ®Google Scholar
• Gupta B, Ghosh KK, Gupta RC. Thymoquinone. In: Gupta RC, editors. Nutraceuticals: Efficacy, Safety and Toxicity. United State of America (USA): Academic Press; 2016. p. 541–550.
   Google Scholar
• Tavakkoli A, Mahdian V, Razavi BM, et al. Review on clinical trials of black seed (Nigella sativa) and its active constituent, thymoquinone. J Pharmacopuncture. 2017 Sep;20(3):179.
   PubMed Web of Science ®Google Scholar
• Dur A, Kose H, Kocyigit A, et al. The anti-inflammatory and antioxidant effects of thymoquinone on ceruleine induced acute pancreatitis in rats. Bratisl Lek Listy. 2016;117(10):614–618.
   PubMed Web of Science ®Google Scholar
• Rathore C, Upadhyay NK, Sharma A, et al. Phospholipid nanoformulation of thymoquinone with enhanced bioavailability: development, characterization and anti-inflammatory activity. J Drug Delivery Sci Technol. 2019 Aug;1(52):316–324.
   Web of Science ®Google Scholar
• Haron AS, Alwi S, Sakinah S, et al. Cytotoxic effect of thymoquinone-loaded nanostructured lipid carrier (TQ-NLC) on liver cancer cell integrated with hepatitis B genome, Hep3B. Evid Based Complement Alternat Med. 2018;2018:1–13.
   Web of Science ®Google Scholar
• Reindl W, Yuan J, Krämer A, et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol. 2008 May 19;15(5):459–466.
   PubMed Web of Science ®Google Scholar
• Negi P, Sharma I, Hemrajani C, et al. Thymoquinone-loaded lipid vesicles: a promising nanomedicine for psoriasis. BMC Complement Altern Med. 2019;19(1):1–9.
   PubMed Web of Science ®Google Scholar
• Pathan SA, Jain GK, Zaidi SM, et al. Stability‐indicating ultra‐performance liquid chromatography method for the estimation of thymoquinone and its application in biopharmaceutical studies. Biomed Chromatogr. 2011;25(5):613–620.
   PubMed Web of Science ®Google Scholar
• Ballout F, Habli Z, Rahal ON, et al. Thymoquinone-based nanotechnology for cancer therapy: promises and challenges. Drug Discov Today. 2018;23(5):1089–1098.
   PubMed Web of Science ®Google Scholar
• Negi P, Sharma G, Verma C, et al. Novel thymoquinone loaded chitosan-lecithin micelles for effective wound healing: development, characterization, and preclinical evaluation. Carbohydr Polym. 2019;23:115659.
   Google Scholar
• El-Far A, Al Jaouni S, Li W, et al. Protective roles of thymoquinone nanoformulations: potential nanonutraceuticals in human diseases. Nutrients. 2018 Sep 25;10(10):1369.
   PubMed Web of Science ®Google Scholar
• Shah M, Choi MH, Ullah N, et al. Synthesis and characterization of PHV-block-mPEG diblock copolymer and its formation of amphiphilic nanoparticles for drug delivery. J Nanosci Nanotechnol. 2010 Jul 1;11(7):5702–5710.
   Web of Science ®Google Scholar
• Bhattacharya S, Ahir M, Patra P, et al. PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials. 2015 May 1;51:91–107.
   PubMed Web of Science ®Google Scholar
• Khan MA, Aldebasi YH, Alsuhaibani SA, et al. Therapeutic potential of thymoquinone liposomes against the systemic infection of Candida albicans in diabetic mice. PLoS ONE. 2018;13(12):e0208951.
   PubMed Web of Science ®Google Scholar
• Alam S, Khan ZI, Mustafa G, et al. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine. 2012;7:5705.
   PubMed Web of Science ®Google Scholar
• Salmani J, Asghar S, Lv H, et al. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules. 2014;19(5):5925–5939.
   PubMed Web of Science ®Google Scholar
• Goyal SN, Prajapati CP, Gore PR, et al. Therapeutic potential and pharmaceutical development of thymoquinone: a multitargeted molecule of natural origin. Front Pharmacol. 2017 Sep;21(8):656.
   Web of Science ®Google Scholar
• Sah E, Sah H. Recent trends in preparation of poly (lactide-co-glycolide) nanoparticles by mixing polymeric organic solution with antisolvent. J Nanomater. 2015 Jan 1;16(1):61.
   Google Scholar
• Sahin A, Esendagli G, Yerlikaya F, et al. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles’ characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol. 2017;45(8):1657–1664.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Pandey VK. Nanoparticles: an overview of preparation. Res Rev. 2016;4:3.
   Google Scholar
• Elieh-Ali-Komi D, Hamblin MR. Chitin and chitosan: production and application of versatile biomedical nanomaterials. Int J Adv Res. 2016;4(3):411.
   PubMedGoogle Scholar
• Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed. 2011;6:765–774.
   PubMed Web of Science ®Google Scholar
• Zafar S, Akhter S, Ahmad I, et al. Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of docetaxel and thymoquinone by chitosan grafted lipid nanocapsules: formulation optimization, in vitro and in vivo studies. Colloids Surf B Biointerfaces. 2019;23:110603.
   Google Scholar
• Othman N, Masarudin M, Kuen C, et al. Synthesis and optimization of chitosan nanoparticles loaded with L-ascorbic acid and thymoquinone. Nanomaterials. 2018;8(11):920.
   Web of Science ®Google Scholar
• Fakhria A, Gilani SJ, Imam SS. Formulation of thymoquinone loaded chitosan nano vesicles: in-vitro evaluation and in-vivo anti-hyperlipidemic assessment. J Drug Delivery Sci Technol. 2019;50:339–346.
   Web of Science ®Google Scholar
• Kothamasu P, Kanumur H, Ravur N, et al. Nanocapsules: the weapons for novel drug delivery systems. Bioimpacts. 2012;2(2):71.
   PubMedGoogle Scholar
• Amgoth C, Kumar K, Medhi H, et al. Polymeric nanocapsules for drug delivery applications. Nanotechnology for Animal Health and Production. 2014:99–123. Editors: Sudhi Ranjan Garg. DAYA PUBLISHING HOUSE, NEW DELHI.
   Google Scholar
• Rani R, Dahiya S, Dhingra D, et al. Antidiabetic activity enhancement in streptozotocin+ nicotinamide–induced diabetic rats through combinational polymeric nanoformulation. Int J Nanomedicine. 2019;14:4383–4395.
   PubMed Web of Science ®Google Scholar
• Rai R, Alwani S, Badea I. Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications. Polymers. 2019 Apr;11(4):745.
   PubMed Web of Science ®Google Scholar
• Semete B, Booysen L, Lemmer Y, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine. 2010;6:662–671.
   PubMed Web of Science ®Google Scholar
• Dinarvand R, Sepehri N, Manoochehri S, et al. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011;6:877.
   PubMed Web of Science ®Google Scholar
• Nallamuthu I, Parthasarathi A, Khanum F. Thymoquinone-loaded PLGA nanoparticles: antioxidant and anti-microbial properties. Int Curr Pharm J. 2013 Nov 14;2(12):202–207.
   Google Scholar
• ARASOĞLU T, Derman S, MANSUROĞLU B, et al. Preparation, characterization, and enhanced antimicrobial activity: quercetin-loaded PLGA nanoparticles against foodborne pathogens. Turk J Biol. 2017;41(1):127–140.
   Web of Science ®Google Scholar
• Ganea GM, Fakayode SO, Losso JN, et al. Delivery of phytochemical thymoquinone using molecular micelle modified poly (D, L lactide-co-glycolide)(PLGA) nanoparticles. Nanotechnology. 2010;21(28):285104.
   PubMed Web of Science ®Google Scholar
• Govender S, Pillay V, Chetty DJ, et al. Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres. Int J Pharmaceut. 2005;306(1):24–40.
   PubMed Web of Science ®Google Scholar
• Khan MA, Tania M, Wei C, et al. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition. Oncotarget. 2015;6(23):19580.
   PubMedGoogle Scholar
• Khan MA, Tania M, Fu S, et al. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget. 2017;8(31):51907.
   PubMedGoogle Scholar
• Mona MA, Mottaleb A. Biodegradable thymoquinone nanoparticles for higher therapeutic efficiency in murine colorectal cancer. Ijppr. Human. 2016;7:436–450.
   Google Scholar
• Kaseb AO, Chinnakannu K, Chen D, et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone refractory prostate cancer. Cancer Res. 2007;67:7782–7788.
   PubMed Web of Science ®Google Scholar
• Sethi G, Ahn K, Aggarwal B. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008;6:1059–1070.
   PubMed Web of Science ®Google Scholar
• Yi T, Cho S, Yi Z, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 2008;7: 1789–79.
   Web of Science ®Google Scholar
• Banerjee S, Kaseb A, Wang Z, et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 2009;69:5575–5583.
   PubMed Web of Science ®Google Scholar
• Khan MA, Tania M, Fu J. Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics. Drug Discov Today. 2019;24(12):2315–2322.
   PubMed Web of Science ®Google Scholar
• Verma D, Thakur PS, Padhi S, et al. Design expert assisted nanoformulation design for co-delivery of topotecan and thymoquinone: optimization, in vitro characterization and stability assessment. J Mol Liq. .2017;242:382–394.
   Web of Science ®Google Scholar
• Schneider-Stock R, Fakhoury IH, Zaki AM, et al. Thymoquinone: fifty years of success in the battle against cancer models. Drug Discov Today. 2014;19(1):18–30.
   PubMed Web of Science ®Google Scholar
• D’souza AA, Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv. 2016;13(9):1257–1275.
   PubMed Web of Science ®Google Scholar
• Sun H, Guo B, Cheng R, et al. Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin. Biomaterials. 2009;30:6358e66.
   Web of Science ®Google Scholar
• Wu L, Tang C, Yin C. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm. 2010;36:439e48.
   Web of Science ®Google Scholar
• Sharma N, Baldi A. Exploring versatile applications of cyclodextrins: an overview. Drug Deliv. 2016;23(3):729–747.
   Web of Science ®Google Scholar
• Jacob S, Nair AB. Cyclodextrin complexes: perspective from drug delivery and formulation. Drug Dev Res. 2018;79(5):201–217.
   PubMed Web of Science ®Google Scholar
• Abu-Dahab R, Odeh F, Ismail SI, et al. Preparation, characterization and antiproliferative activity of thymoquinone-β-cyclodextrin self assembling nanoparticles. Die Pharmazie- Int J Pharm Sci. 2013;68(12):939–944.
   Google Scholar
• Khattabi AM, Talib WH, Alqdeimat DA. The effect of polymer length on the in vitro characteristics of a drug loaded and targeted silica nanoparticles. Saudi Pharm J. 2018;26(7):1022–1026.
   PubMed Web of Science ®Google Scholar
• Qi D, Cao Z, Ziener U. Recent advances in the preparation of hybrid nanoparticles in miniemulsions. Adv Colloid Interface Sci. 2014;211:47–62.
   PubMed Web of Science ®Google Scholar
• Madni A, Tahir N, Rehman M, et al. Hybrid Nano-carriers for potential drug delivery. Adv Technol Delivering Ther. 2017;11:53.
   Google Scholar
• Xiao-Yu X, Ying-Xian Z, Ju-Yuan B, et al. Evaluation of neuroprotective effect of thymoquinone nanoformulation in the rodent cerebral ischemia-reperfusion model. Biomed Res Int. 2016;(1):1–11.
   Web of Science ®Google Scholar
• Kumar SK, Devi PR, Harish S, et al. Synthesis and characterisation of peg modified chitosan nanocapsules loaded with thymoquinone. IET Nanobiotechnol. 2016;11(1):104–112.
   Web of Science ®Google Scholar
• Ahmad R, Mohd Kaus NH, Hamid S. Synthesis and characterization of PLGA-PEG thymoquinone nanoparticle and its cytotoxicity effects in tamoxifen-resistant breast cancer cells. Biomedical Res Ther. 2017:4(S):1–18.
   Google Scholar
• Francesco C, Francesco L. New methods for lipid nanoparticles preparation. Recent Pat Drug Deliv Formul. 2011;5:201–213.
   PubMedGoogle Scholar
• Wen J, Chen G, Chen S. Nanostructured Lipid Carriers. In: Roohinejad S, Greiner R, Oey I, Wen J, editors. Emulsion-based Systems for Delivery of Food Active Compounds: Formation, Application, Health and Safety. Germany: Wiley Publishers; 2018. p. 1-312.
   Google Scholar
• Abdelwahab SI, Sheikh BY, Taha MM, et al. Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomedicine. 2013;8:2163.
   PubMed Web of Science ®Google Scholar
• Elmowafy M, Samy A, Raslan MA Enhancement of Bioavailability and Pharmacodynamic Effects of Thymoquinone via Nanostructured Lipid Carrier (NLC) Formulation. American Association of Pharmaceutical Sciences PharmSciTech 2015.
   Google Scholar
• Keat Ng W, Yazan LS, Yap LH. Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa). Bio Med Res Int. 2015;4:1–10.
   Google Scholar
• Rathore C, Upadhyaya N, Kaundal R, et al. Enhanced oral bioavailability and hepatoprotective activity of thymoquinone in the form of phospholipidic nano-constructs. Expert Opin Drug Deliv. 2020:1–17. DOI:10.1080/17425247.2020.1716728.
   PubMed Web of Science ®Google Scholar
• Mishra V, Bansal K, Verma A, et al. Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics. 2018;10(4):191.
   PubMed Web of Science ®Google Scholar
• Bayón-Cordero L, Alkorta I, Arana L. Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. Nanomaterials. 2019;9(3):474.
   Web of Science ®Google Scholar
• Singh A, Ahmad I, Akhter S, et al. Nanocarrier based formulation of Thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies. Colloids Surf B Biointerfaces. 2013;102:822–832.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Thangarajan S. A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington’s disease-like symptoms in wistar rats. Chem Biol Interact. 2016;5(25):25–36.
   Web of Science ®Google Scholar
• Ramachandran S, Thangarajan S. Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington’s disease. Metab Brain Dis. 2018;31:1–2.
   Google Scholar
• Kamboj S, Saini V, Bala S. Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement. Sci World J. 2014;2014:1–8.
   Web of Science ®Google Scholar
• Rajput S, Puvvada N, Kumar BP, et al. Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm. 2015;12(12):4214–4225.
   PubMed Web of Science ®Google Scholar
• Imam SS, Aqil M, Akhtar M, et al. Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study. Drug Deliv. 2015;22(8):1059–1070.
   PubMed Web of Science ®Google Scholar
• Khatoon M, Shah KU, Din FU, et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 2017;24(2):56–69.
   PubMed Web of Science ®Google Scholar
• Sayeed S, Imam SS, Najmi AK, et al. Nonionic surfactant based thymoquinone loaded nanoproniosomal formulation: in vitro physicochemical evaluation and in vivo hepatoprotective efficacy. Drug Dev Ind Pharm. 2017;43(9):1413–1420.
   PubMed Web of Science ®Google Scholar
• Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. Adv Pharm Bull. 2017;7(1):3.
   PubMed Web of Science ®Google Scholar
• Hussain A, Singh S, Sharma D, et al. Elastic liposomes as novel carriers: recent advances in drug delivery. Int J Nanomedicine. 2017;12:5087.
   PubMed Web of Science ®Google Scholar
• Odeh F, Ismail SI, Abu-Dahab R. Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Deliv. 2012;19(8):371–377.
   PubMed Web of Science ®Google Scholar
• Khan MA, Aljarbou AN, Khan A, et al. Liposomal thymoquinone effectively combats fluconazole-resistant Candida albicans in a murine model. Int J Biol Macromol. 2015;76:203–208.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Akhter S, Anwar M, et al. Supercritical anti-solvent technique assisted synthesis of thymoquinone liposomes for radioprotection: formulation optimization, in-vitro and in-vivo studies. Int J Pharm. 2017;523(1):398–409.
   PubMed Web of Science ®Google Scholar
• Krstić M, Medarević Đ, Đuriš J, et al. Lipid Nanocarriers for Drug Targeting. In: Self-nanoemulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs. In: Grumezescu A, editors. Lipid Nanocarriers for Drug Targeting. Romania: William Andrew Publishing; 2018. p. 473–508.
   Google Scholar
• Rehman FU, Shah KU, Shah SU, et al. From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS). Expert Opin Drug Deliv. 2017;14(11):1325–1340.
   PubMed Web of Science ®Google Scholar
• Kalam MA, Raish M, Ahmed A, et al. Oral bioavailability enhancement and hepatoprotective effects of thymoquinone by self-nanoemulsifying drug delivery system. Mater Sci Eng C. 2017;76:319–329.
   PubMed Web of Science ®Google Scholar
• Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123–127.
   PubMedGoogle Scholar
• Sharma N, Bansal M, Visht S, et al. Nanoemulsion: A new concept of delivery system. Chron Young Sci. 2010;1(2):2.
   Google Scholar
• Tubesha Z, Imam M, Mahmud R, et al. Study on the potential toxicity of a thymoquinone-rich fraction nanoemulsion in Sprague Dawley rats. Molecules. 2013;18(7):7460–7472.
   PubMed Web of Science ®Google Scholar
• Dehghani H, Hashemi M, Entezari M, et al. The comparison of anticancer activity of thymoquinone and nanothymoquinone on human breast adenocarcinoma. Iran J Pharm Res. 2015;14(2):539.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Alam MA, et al. Quantification and evaluation of thymoquinone loaded mucoadhesive nanoemulsion for treatment of cerebral ischemia. Int J Biol Macromol. 2016;88:320–332.
   PubMed Web of Science ®Google Scholar
• Ismail N, Ismail M, Azmi N, et al. Thymoquinone-rich fraction nanoemulsion (TQRFNE) decreases Aβ40 and Aβ42 levels by modulating APP processing, up-regulating IDE and LRP1, and down-regulating BACE1 and RAGE in response to high fat/cholesterol diet-induced rats. Biomed Pharmacother. 2017;95:780–788.
   PubMed Web of Science ®Google Scholar
• Zidan AA, El-Ashmawy NE, Khedr EG, et al. Loading of doxorubicin and thymoquinone with F2 gel nanofibers improves the antitumor activity and ameliorates doxorubicin-associated nephrotoxicity. Life Sci. 2018;207:461–470.
   PubMed Web of Science ®Google Scholar